In the last trading session, 2.69 million shares of the Immunovant Inc (NASDAQ:IMVT) were traded, and its beta was 0.67. Most recently the company’s share price was $19.52, and it changed around -$0.89 or -4.36% from the last close, which brings the market valuation of the company to $3.32B. IMVT currently trades at a discount to its 52-week high of $39.55, offering almost -102.61% off that amount. The share price’s 52-week low was $19.86, which indicates that the current value has fallen by an impressive -1.74% since then. We note from Immunovant Inc’s average daily trading volume that its 10-day average is 1.58 million shares, with the 3-month average coming to 1.09 million.
Immunovant Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.15. If we narrow it down even further, the data shows that 0 out of 14 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 1 recommended IMVT as a Hold, whereas 10 deemed it a Buy, and 0 rated it as Underweight. Immunovant Inc is expected to report earnings per share of -0.72 for the current quarter.
Immunovant Inc (NASDAQ:IMVT) trade information
Instantly IMVT has showed a red trend with a performance of -4.36% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 23.10 on recent trading dayincreased the stock’s daily price by 15.5%. The company’s shares are currently down -21.19% year-to-date, but still down -6.15% over the last five days. On the other hand, Immunovant Inc (NASDAQ:IMVT) is -17.39% down in the 30-day period. We can see from the shorts that 12.83 million shares have been sold at a short interest cover period of 12.19 day(s).
The consensus price target as assigned by Wall Street analysts is $51, which translates to bulls needing to increase their stock price by 61.73% from its current value. Analyst projections state that IMVT is forecast to be at a low of $51 and a high of $51.
Forecasts for the next quarter put sales growth at 0.00%.
Immunovant Inc earnings are expected to increase by -51.63% in 2025, but the outlook is negative -21.13% per year for the next five years.
IMVT Dividends
Immunovant Inc’s next quarterly earnings report is expected to be released in March.
Immunovant Inc (NASDAQ:IMVT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 58.10% of Immunovant Inc shares, and 47.06% of them are in the hands of institutional investors. The stock currently has a share float of 112.31%. Immunovant Inc stock is held by 267.0 institutions, with FMR LLC being the largest institutional investor. By 2024-06-30, it held 7.5915% of the shares, which is about 10.48 million shares worth $276.77 million.
VANGUARD GROUP INC, with 4.7138% or 6.51 million shares worth $171.86 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
